Zamerovimab

Names

[ CAS No. ]:
2419087-87-7

[ Name ]:
Zamerovimab

Biological Activity

[Description]:

Zamerovimab (CTB011; SYN023) is a mixture of human monoclonal antibodies consisting of CTB011 and CTB012. Zamerovimab binds to non-overlapping epitopes on rabies virus (RABV) glycoprotein, where CTB011 binds to antigenic site III. Zamerovimab can be used in rabies studies[1].

[Related Catalog]:

Research Areas >> Infection

Signaling Pathways >> Others >> Others

[In Vitro]

Zamerovimab (CTB011; SYN023) (0.001-100 μg/mL, 4 h) 在 CVS 感染的 BSR 细胞中，以剂量依赖性方式诱导细胞毒性，促进病毒清除，也表明细胞毒性与表达 G 蛋白的细胞特异性相关，而这些细胞被 CTB011 靶向[1]。

[In Vivo]

Zamerovimab (CTB011; SYN023) (0.03-1.0 mg/kg，右腓肠肌注射，一次，35 天) 可以以剂量依赖性方式增加感染了狂犬病病毒RABV BD06 的叙利亚仓鼠的存活率，在剂量分别为 0.03、0.1、0.3、1.0 mg/kg 时，存活率分别为 58%，83%，100% 和 100%[1]。

[References]

[1]. Tzu-Yuan Chao, et al. SYN023, a novel humanized monoclonal antibody cocktail, for post-exposure prophylaxis of rabies. PLoS Negl Trop Dis. 2017 Dec 20;11(12):e0006133.

Chemical & Physical Properties

No Any Chemical & Physical Properties

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.